AngioDynamics
ANGO
AngioDynamics (ANGO) earnings history
Most recent quarter
- Fiscal period
- Q4 2026
- Period end
- May 31, 2026
- EPS actual
- −$0.07
- EPS estimate
- −$0.09
- EPS surprise
- +21.96%
- Revenue surprise
- +7.93%
- Revenue
- $86.6M
- Revenue estimate
- $80.2M
- Reported
- Jul 14, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2026 | Jul 14, 2026 | −$0.09 | −$0.07 | +21.96% | $86.6M | SEC |
| Q3 2026 | Apr 2, 2026 | −$0.11 | $0.02 | +118.18% | $78.4M | SEC |
| Q1 2026 | Oct 2, 2025 | −$0.12 | −$0.10 | +18.30% | $75.7M | SEC |
| Q4 2025 | Jul 15, 2025 | −$0.12 | −$0.03 | +74.73% | $80.2M | SEC |
| Q3 2025 | Apr 2, 2025 | −$0.13 | −$0.08 | +38.46% | $72.0M | SEC |
| Q2 2025 | Jan 8, 2025 | −$0.11 | −$0.04 | +63.64% | $73.0M | SEC |
| Q1 2025 | Oct 3, 2024 | −$0.15 | −$0.11 | +25.02% | $67.5M | SEC |
| Q4 2024 | Jul 16, 2024 | −$0.17 | −$0.06 | +64.01% | $71.1M | SEC |
| Q3 2024 | Apr 4, 2024 | −$0.16 | −$0.16 | −3.23% | $66.0M | SEC |
| Q2 2024 | Jan 5, 2024 | −$0.07 | −$0.05 | +32.16% | $79.1M | SEC |
| Q1 2024 | Oct 4, 2023 | −$0.13 | −$0.12 | +7.69% | $78.7M | SEC |
| Q4 2023 | Jul 12, 2023 | $0.02 | $0.02 | −7.41% | $91.1M | SEC |
| Q3 2023 | Mar 30, 2023 | −$0.01 | −$0.03 | −300.00% | $80.7M | SEC |
| Q2 2023 | Jan 5, 2023 | −$0.01 | $0.01 | +200.00% | $85.4M | SEC |
| Q1 2023 | Oct 6, 2022 | −$0.02 | −$0.06 | −166.67% | $81.5M | — |
| Q4 2022 | Jul 12, 2022 | $0.01 | $0.01 | +33.33% | $87.0M | — |
| Q3 2022 | Apr 7, 2022 | −$0.01 | $0.03 | +340.00% | $74.0M | — |
| Q2 2022 | Jan 6, 2022 | $0.00 | −$0.02 | +0.00% | $78.3M | — |
| Q1 2022 | Sep 30, 2021 | −$0.05 | −$0.02 | +55.56% | $77.0M | — |
| Q4 2021 | Jul 13, 2021 | −$0.00 | $0.00 | +100.00% | $76.8M | — |
Quarterly revenue
Frequently asked questions
When did AngioDynamics (ANGO) last report earnings?
AngioDynamics last reported on Jul 14, 2026, covering fiscal Q4 2026.
Did ANGO beat earnings estimates?
Yes. AngioDynamics reported EPS of −$0.07 for Q4 2026 against a −$0.09 estimate — a 21.96% beat.
How much revenue did ANGO report last quarter?
AngioDynamics reported $86.6M in revenue for Q4 2026, against a consensus estimate of $80.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.